108 results
10-12G
EX-10.6
ATXI
Avenue Therapeutics Inc
30 Dec 15
Registration of securities
12:00am
to time.
3.5 Benefits. Executive shall, in accordance with Company policy and the applicable plan documents, be eligible to participate in benefits under … , Executive, or her estate, as the case may be, will be entitled to receive the compensation and benefits earned through the effective date of termination
10-12G
EX-10.6
ATXI
Avenue Therapeutics Inc
12 Jan 17
Registration of securities
12:00am
to time.
3.5 Benefits. Executive shall, in accordance with Company policy and the applicable plan documents, be eligible to participate in benefits under … , Executive, or her estate, as the case may be, will be entitled to receive the compensation and benefits earned through the effective date of termination
8-K
EX-10.10
ATXI
Avenue Therapeutics Inc
14 Nov 18
Entry into a Material Definitive Agreement
12:53pm
with regard to the separation benefits provided to Executive in certain circumstances; and
WHEREAS, in light of the foregoing, Executive and the Company … the following separation benefits: (i) the Company will continue Executive’s Base Salary (at the rate in effect as of the termination) for a period
10-12G
EX-10.7
ATXI
Avenue Therapeutics Inc
12 Jan 17
Registration of securities
12:00am
of the benefits of Awards granted to participants located in the United States or such other jurisdictions and to further the objectives of the Plan … in an Award Certificate that the Participant’s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture
8-K
EX-10.4
8w1wr5pjklf428hbg
14 Nov 18
Entry into a Material Definitive Agreement
12:53pm
10-12G
EX-10.7
0flx1vafaq qc1s07
30 Dec 15
Registration of securities
12:00am
10-Q
gvq0pns
12 May 17
Quarterly report
12:00am
10-12G
3s0zwdc7q
12 Jan 17
Registration of securities
12:00am
10-K
e2p5hcif0x5fm walzg
1 Mar 18
Annual report
12:00am
8-K
EX-10.9
n1p8a57co f8uo
14 Nov 18
Entry into a Material Definitive Agreement
12:53pm
8-K
EX-99.1
vaeo 5i24v1rg45yy
25 May 18
Regulation FD Disclosure
8:30am
8-K
EX-10.1
8yb m6gn16cou1pqvrj
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
10-12G/A
eyv txexf5svhzc
6 Mar 17
Registration of securities (amended)
12:00am
8-K
EX-99.1
l46jxov3 g9gem00
16 Feb 22
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
7:39am